New drug cocktail targets deadly bowel cancer mutation
NCT ID NCT06008119
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial is testing whether a combination of two targeted drugs, tunlametinib and vemurafenib, can help people with a specific genetic mutation (BRAF V600E) in metastatic colorectal cancer. About 165 participants will be randomly assigned to receive either the drug combo or standard chemotherapy. The main goal is to see if the combo slows cancer growth better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tunlametinib plus vemurafenib
What this could lead to
If successful, this combination could offer a new targeted treatment option for people with a specific genetic subtype of advanced colorectal cancer, potentially slowing disease progression.
What could go wrong
This is an early-stage Phase 3 trial with only 165 participants. The combination may not prove more effective than standard chemotherapy, and side effects from the two drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Oncology Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••